Treatment of cognitive deficits in schizophrenia - Part 2: Pharmacological strategies

被引：5

作者：

Roesch-Ely, D. ^{[2
]}

Pfueller, U. ^{[1
,2
]}

Mundt, C. ^{[2
]}

Mueller, U. ^{[3
]}

Weisbrod, M. ^{[1
,2
]}

机构：

[1] SRH Klinikum Karlsbad Langensteinbach, Klin Psychiat & Psychotherapie, Karlsbad, Germany

[2] Univ Klinikum Heidelberg, Klin Allgemeine Psychiat, Zentrum Psychosoziale Med, D-69115 Heidelberg, Germany

[3] Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 1TN, England

来源：

NERVENARZT | 2010年 / 81卷 / 05期

关键词：

Cognition-enhancing drugs; Cognition; Schizophrenia; Psychopharmacology; Treatment; RANDOMIZED CONTROLLED-TRIAL; WORKING-MEMORY; DOUBLE-BLIND; ANTIPSYCHOTIC-DRUGS; 1ST-EPISODE SCHIZOPHRENIA; PREFRONTAL CORTEX; NEGATIVE SYMPTOMS; ADD-ON; DOPAMINERGIC MODULATION; RECEPTOR ANTAGONIST;

D O I：

10.1007/s00115-009-2919-6

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Cognitive deficits in schizophrenia are a clinically relevant symptom dimension and one of the best predictors for functional outcome. Pharmacological treatment of cognitive deficits in schizophrenia is still a challenge. The objective of this article is to present a detailed review of the literature on strategies for the pharmacological treatment of cognitive deficits. It is not clear whether first-generation antipsychotics have a genuine positive influence on cognition. There is only sparse evidence for the positive effect of second-generation antipsychotics on cognitive processes. Furthermore it is not evident that second-generation antipsychotics are more beneficial than first-generation antipsychotics in the treatment of cognitive deficits. The add-on use of substances which directly influence cognitive processes, so-called cognition-enhancing drugs is more promising.

引用

页码：564 / 576

页数：13

共 50 条

[31] Cognitive deficits in adolescents with schizophrenia undergoing antipsychotic treatment
Chabrol, H
Peresson, G
Bonnet, D
AMERICAN JOURNAL OF PSYCHIATRY, 1999, 156 (03): : 497 - 497
[32] Pharmacological treatment of cognitive deficits in Alzheimer's disease - Reply
Brodaty, H
Hecker, JR
Snowdon, JA
Green, A
Ames, DJ
MEDICAL JOURNAL OF AUSTRALIA, 2002, 176 (06) : 297 - 298
[33] Pharmacological treatment of cognitive deficits in nondementing mental health disorders
Robbins, Trevor W.
DIALOGUES IN CLINICAL NEUROSCIENCE, 2019, 21 (03) : 301 - 308
[34] Pharmacological therapy of cognitive deficits
Gottfries, CG
NEUROPSYCHIATRY IN OLD AGE: AN UPDATE, 1996, 3 : 129 - 143
[35] Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia
Goff, Donald C.
WORLD PSYCHIATRY, 2013, 12 (02) : 99 - 107
[36] Cognitive function in schizophrenia - Deficits, functional consequences, and future treatment
Sharma, T
Antonova, L
PSYCHIATRIC CLINICS OF NORTH AMERICA, 2003, 26 (01) : 25 - +
[37] Pharmacotherapy of cognitive deficits in schizophrenia
Opler, Lewis A.
Medalia, Alice
Opler, Mark G.
Stahl, Stephen M.
CNS SPECTRUMS, 2014, 19 (02) : 142 - 156
[38] REMEDIATION OF COGNITIVE DEFICITS IN SCHIZOPHRENIA
BELLACK, AS
MUESER, KT
MORRISON, RL
TIERNEY, A
PODELL, K
AMERICAN JOURNAL OF PSYCHIATRY, 1990, 147 (12): : 1650 - 1655
[39] Familial cognitive deficits in schizophrenia
Hoff, AL
Svetina, C
Maurizio, AM
Crow, TJ
Spokes, K
DeLisi, LE
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2005, 133B (01) : 43 - 49
[40] Cognitive deficits and the schizophrenia spectrum
Mitropoulou, V
Bushnoe, L
Silverman, JM
Siever, LJ
BIOLOGICAL PSYCHIATRY, 2000, 47 (08) : 34S - 34S

← 1 2 3 4 5 →